Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature

Yishi Zhang; Wan He; Ke Zhan; Luobin Zhang; Hua Cao; Ruilian Xu

doi:10.3389/fonc.2023.1153233

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature

Front Oncol. 2023 May 16:13:1153233. doi: 10.3389/fonc.2023.1153233. eCollection 2023.

Authors

Yishi Zhang¹, Wan He¹, Ke Zhan², Luobin Zhang¹, Hua Cao¹, Ruilian Xu¹

Affiliations

¹ Department of Oncology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
² Department of Spine Surgery, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.

Abstract

Malignant mesothelioma that originates from mediastinal (MMM) is a rare form of malignant pleural mesothelioma (MPM). The prognosis of advanced stage MPM was poor, and the traditional treatment was chemotherapy. Here, we present a patient with MMM that was treated with anlotinib, a multitargeted tyrosine kinase inhibitor (TKI) who had a 24-month progression-free survival (PFS). Further review of the literature showed that, despite some explorations of applying small-molecule multitargeted TKIs in the treatment of MPM, until today, no large series had a positive result. Anlotinib had been approved by the China Food and Drug Administration on treating non-small cell lung cancer, soft tissue sarcoma, renal cell carcinoma, and medullary thyroid cancer. We assumed that the ability of anlotinib to target more tyrosine kinase receptors than most of other TKIs could contribute to the long duration of PFS in this case, but further study is needed to further validate the efficacy of anlotinib in treatment of MPM.

Keywords: anlotinib; malignant mesothelioma; malignant pleural mesothelioma; mediastinal mesothelioma; tyrosine kinase inhibitor.

Publication types

Case Reports

Grants and funding

This article was supported by Beijing Science and Technology Innovation Medical Development Foundation (grant number KC2021-JX-0186-15). The funder was not involved in the study design, collection, analysis, the writing of this article, or the decision to submit it for publication.